AstraZeneca’s stock price tumbled 14 percent on Monday morning after the company rejected...

As the Astra Zeneca Pfizer deal gets more bad tempered and political, what are the side effects...

Leading Bio tech firms, have seen around thirty percent growth in the last year and prospects...

Peter Garnry, Saxo Bank's Head of Equity Strategy, analyses the US earnings season so far and...

Saxo Bank's Head of Equity Strategy, Peter Garnry, analyses Weibo's IPO. Often called the...

It’s been looking bleak for equities, the end of a five year bull run, doom and gloom abound....

Brian Colello, Senior Equity Analyst at Morningstar, discusses why he thinks Apple's (AAPL)...

Michael Jarman has been looking at the trading week and what the markets may bring as we head...

Whilst most analysts suggest you should be overweight bonds, mainly because we the economy has...